Clinical efficacy and safety of cefepime-tazobactam in hospitalized patients in South India

Infect Dis (Lond). 2018 May;50(5):391-394. doi: 10.1080/23744235.2017.1410284. Epub 2017 Nov 30.
No abstract available

Publication types

  • Letter

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Anti-Bacterial Agents / adverse effects
  • Anti-Bacterial Agents / therapeutic use*
  • Cefepime
  • Cephalosporins / administration & dosage
  • Cephalosporins / adverse effects*
  • Cephalosporins / therapeutic use
  • Escherichia coli / drug effects
  • Escherichia coli / enzymology
  • Escherichia coli Infections / drug therapy
  • Escherichia coli Infections / epidemiology
  • Female
  • Hospitalization / statistics & numerical data*
  • Humans
  • India / epidemiology
  • Klebsiella Infections / drug therapy
  • Klebsiella Infections / epidemiology
  • Klebsiella pneumoniae / drug effects
  • Klebsiella pneumoniae / isolation & purification
  • Male
  • Middle Aged
  • Penicillanic Acid / administration & dosage
  • Penicillanic Acid / adverse effects
  • Penicillanic Acid / analogs & derivatives*
  • Penicillanic Acid / therapeutic use
  • Piperacillin / therapeutic use
  • Tazobactam
  • Treatment Outcome
  • Young Adult
  • beta-Lactamases / biosynthesis
  • beta-Lactamases / drug effects

Substances

  • Anti-Bacterial Agents
  • Cephalosporins
  • Cefepime
  • Penicillanic Acid
  • beta-Lactamases
  • Tazobactam
  • Piperacillin